All News
Might Synovial Biopsy Predict Rheumatoid Treatment Responses?
d
EurekAlert!
Multi-modal analysis of rheumatoid arthritis (RA) synovitis pathotypes enables more accurate choices of first line cDMARDs treatment, suggesting a predictive value to synovial biopsy.
Read Article
Cohort from Netherlands 400+ PsA pts IR first bioDMARD
300+ switched TNFi->IL-17i, 99 cycled TNFi->TNFi
3year retention rates
12 mo 75% cyclers 80% swappers
24mo 60% cyclers 56% swappers
No difference in treatment failure or DAS28 CRP
#EULAR2024 @RheumNow POS0278 https://t.co/J8ONjVAFqG
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR2024 OP0193 Watch out, blinatumomab will BiTE! Bi-specific T-cell engagers (BiTEs), kill Bcells by engaging Tcells. In 6 refractory #RA patients (failed 3 x ts/bDMARDs), deep blood & tissue depletion were met, good response. Brief raised temp but no cytokine storm @RheumNow https://t.co/OmxSbTXfZq
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
RA patients on abatacept have an appalling immunogenic response to Shingrix. Humoral fades away in the first year, and an absence of cellular responses.
Alarming and need strategies to combat this #EULAR2024 POS0620 Winthrop/@RADoctor @RheumNow https://t.co/8gY9ocLBDp
David Liew drdavidliew ( View Tweet)
#opportunistic inf in #autoimmune dz
🎤 @khyrich
👉#herpes zost is ⬆️⬆️,esp😳#lupus (💉 >18yo🇺🇸)
👉#HBV react ⬆️⬆️ w/ RTX (9.1%) >>TNFi, JAKi, IL-6
👉 🙅♂️ #TB repeat 🧪 on #DMARD if 🚫new risk fact/gap⚠️
🔗#eular 2022 guide:
https://t.co/PIpGpTrH28
#eular2024
#rheumx
@RheumNow https://t.co/kouXvradiC
Artem Minalyan, MD, DABOM AMinalyan ( View Tweet)
#opportunistic inf in #autoimmune dz
🎤 @khyrich
👉#herpes zost is ⬆️⬆️,esp😳#lupus (💉 >18yo🇺🇸)
👉#HBV react ⬆️⬆️ w/ RTX (9.1%) >>TNFi, JAKi, IL-6
👉 🙅♂️ #TB repeat 🧪 on #DMARD if 🚫new risk fact/gap⚠️
🔗#eular 2022 guide:
https://t.co/PIpGpTrH28
#eular2024
#rheumx
@RheumNow https://t.co/kouXvradiC
Artem Minalyan, MD, DABOM AMinalyan ( View Tweet)
Approach to TB screening prior
to commencing biologics. Hyrich K #EULAR2024 @RheumNow https://t.co/j3PI0PHpqW
Dr. Antoni Chan synovialjoints ( View Tweet)
Cycle or swap 2? Post failure to a first TNFi in patients with PsA, there was no difference in cycle versus swap to IL17i for drug retention rate or disease activity. In male PsA patients a cycle strategy had a longer drug retention rate compared to a swap (IL-17i) strategy.… https://t.co/5BykvDwFWV https://t.co/GfcnIltV2A
Dr. Antoni Chan synovialjoints ( View Tweet)
Cycle or swap 2? Post failure to a first TNFi in patients with PsA, there was no difference in cycle versus swap to IL17i for drug retention rate or disease activity. In male PsA patients a cycle strategy had a longer drug retention rate compared to a swap (IL-17i) strategy.… https://t.co/5BykvDwFWV https://t.co/GfcnIltV2A
Dr. Antoni Chan synovialjoints ( View Tweet)
#EULAR2024 Please find our Day 1 & Day 2 Recap of selective abstracts/research presented at the conference 😃@RheumNow @DrMiniDey
https://t.co/AHl18gS7gF https://t.co/LEoa9rBNly
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 Please find our Day 1 & Day 2 Recap of selective abstracts/research presented at the conference 😃@RheumNow @DrMiniDey
https://t.co/AHl18gS7gF https://t.co/LEoa9rBNly
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0295 Approriate patient stratification matters in trials. H2H RCT of Tocilizumab vs Rituximab in refractory #SSc-ILD (failed CyC), stratified based on RNA-seq of lungs biopsy showed improved efficacy in TCZ with low B-cell lineage expression signature @RheumNow https://t.co/7ME3Bd2PeM
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 POS0257 One for the future. Phase 2A RCT showed KPG-818, a Novel Cereblon Modulator (targets Aiolos & Ikaros) was well tolerated with
efficacy signal (SLEDAI-2K & CLASI-50). Effect and safety profile were numerically better in the lowest dose @RheumNow https://t.co/Bjk9zBRmVo
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Does TCZ switch off GCA histopathologically?
GCA pts still on TCZ (median 2.4y duration) had repeat temporal artery biopsy (contralat)
Despite serological remission on TCZ, a heap had active histopath findings & PET still active. Scary
#EULAR2024 OP0233 Reggio Emilia @RheumNow https://t.co/TKBUP5p4R0
David Liew drdavidliew ( View Tweet)
EULAR 2024 – Day 2 Report (A Difficult RA Day)
Day 2 at EULAR 2024 was a big poster day for many with several good sessions and oral presentations on Preventing RA, new vasculitis therapies and a session devoted to the 50th anniversary of the Moll & Wright Criteria.
Read Article
Dual seropositivity and shared epitopes in RA: friends or foes?
Dual seropositivity (rheumatoid factor and/or anti-citrullinated protein antibodies) as well as shared epitope are known to be associated with poor prognosis and structural damage in RA.
Read Article
Greatest chance of sustained drug-free remission (DFR) is seen in early RA pts, NEVER requiring a biologic (esp if seronegative blue line). ERA on biologics never achieve DFR (yellow). Leiden EAC clinic study of 627 ERA pts Abstr# POS0615 #EULAR2024 https://t.co/zpCG6oSE3T
Dr. John Cush RheumNow ( View Tweet)
lanalumab (anti-baff) LTE 1/3 to 1/2 LLDAS/DORIS remission at 52 wks, reduction autoabs etc - looking very promising @rheumnow #EULAR2024
Peter Nash drpnash ( View Tweet)
Day 1 #EULAR2024 Do you want to learn about the effectiveness of rituximab for systemic features of #Sjogren and potential strategies to overcome non-response? Please come to my talk today (OP0076) and say hi 👋🏼 😃 Room C7 at 1720 hr CET @RheumNow https://t.co/uo2ivC5AeY
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Biosimilar uptake across the world.
Interesting that rich countries use more biosimilars - presumably because they have bargaining power - and that means they can access even better pricing.
#EULAR2024 POS0597 Leiden @RheumNow https://t.co/wZgA0JH5uu
David Liew drdavidliew ( View Tweet)